Gambaran Umum
Carisma Therapeutics, Inc., based in the United States, focuses primarily within the biotechnology industry, developing innovative therapies in the realm of cancer treatment. Pioneering the use of engineered macrophages in immunotherapy, Carisma’s notable project includes its proprietary CAR-Macrophage platform, a technology designed to deliver chimeric antigen receptor (CAR) therapies specifically targeting solid tumors. This approach distinctively employs the innate capabilities of macrophages to engulf and digest tumor cells, a method seen as a potential stride forward in addressing the complexities of oncological malignancies. The company has been advancing through various phases of clinical trials aiming to demonstrate efficacy and safety in their targeted therapies, positioning them at the forefront of a niche and emergent segment in cancer treatment innovation.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk Carisma Therapeutics, Inc. per 2025 Jun 30 adalah 10.77 MM.
- Nilai operating income untuk Carisma Therapeutics, Inc. per 2025 Jun 30 adalah -44.11 MM.
- Nilai net income untuk Carisma Therapeutics, Inc. per 2025 Jun 30 adalah -49.38 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-06-30 | 10.77 | -44.11 | -49.38 |
| 2025-03-31 | 19.96 | -50.00 | -50.77 |
| 2024-12-31 | 19.63 | -60.18 | -60.48 |
| 2024-09-30 | 20.27 | -66.77 | -63.80 |
| 2024-06-30 | 20.71 | -75.97 | -72.50 |
| 2024-03-31 | 15.07 | -85.27 | -81.22 |
| 2023-12-31 | 14.92 | -88.73 | -86.88 |
| 2023-09-30 | 14.36 | -81.60 | -82.66 |
| 2023-06-30 | 13.11 | -76.01 | -79.58 |
| 2023-03-31 | 12.26 | -68.98 | -74.56 |
| 2022-12-31 | 9.83 | -56.16 | -61.23 |
| 2022-09-30 | 6.10 | -53.19 | -56.84 |
| 2022-06-30 | 3.52 | -46.69 | -48.75 |
| 2022-03-31 | 0.82 | -41.85 | -43.00 |
| 2021-12-31 | -40.79 | -40.78 | |
| 2020-12-31 | -28.38 | -28.35 |
Laporan Laba Rugi: EPS
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-06-30 | ||
| 2025-03-31 | ||
| 2024-12-31 | ||
| 2024-09-30 | -1.55 | -1.55 |
| 2024-06-30 | -1.77 | -1.77 |
| 2024-03-31 | -2.00 | -2.00 |
| 2023-12-31 | -2.59 | |
| 2023-09-30 | -3.45 | -3.45 |
| 2023-06-30 | -5.53 | -5.53 |
| 2023-03-31 | -15.50 | -15.50 |
| 2022-12-31 | -28.77 | |
| 2022-09-30 | -30.74 | -30.74 |
| 2022-06-30 | -31.00 | -31.00 |
| 2022-03-31 | -32.38 | -32.38 |
| 2021-12-31 | -37.62 | |
| 2020-12-31 | -26.66 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Carisma Therapeutics, Inc. per 2025 Jun 30 adalah -37.34 MM.
- Nilai cash from investing activities untuk Carisma Therapeutics, Inc. per 2025 Jun 30 adalah 0.69 MM.
- Nilai kas dari aktivitas pendanaan untuk Carisma Therapeutics, Inc. per 2025 Jun 30 adalah -1.71 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-06-30 | -37.34 | 0.69 | -1.71 |
| 2025-03-31 | -47.56 | 0.42 | -1.63 |
| 2024-12-31 | -59.92 | -0.12 | 0.34 |
| 2024-09-30 | -67.66 | 10.32 | 1.06 |
| 2024-06-30 | -75.64 | 40.13 | -0.51 |
| 2024-03-31 | -78.07 | 75.99 | -4.21 |
| 2023-12-31 | -81.18 | 72.41 | 62.18 |
| 2023-09-30 | -82.18 | 75.78 | 60.62 |
| 2023-06-30 | -69.50 | 43.74 | 62.45 |
| 2023-03-31 | -65.25 | 28.10 | 66.06 |
| 2022-12-31 | -5.12 | -32.56 | 33.32 |
| 2022-09-30 | 2.86 | -46.71 | 34.78 |
| 2022-06-30 | 1.54 | -45.01 | 34.98 |
| 2022-03-31 | 6.56 | -65.62 | 42.98 |
| 2021-12-31 | -37.33 | -1.87 | 15.96 |
| 2020-12-31 | -27.01 | -0.44 | 72.26 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-06-30 | |||
| 2025-03-31 | |||
| 2024-12-31 | |||
| 2024-09-30 | |||
| 2024-06-30 | |||
| 2024-03-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 | |||
| 2022-09-30 | |||
| 2022-06-30 | |||
| 2022-03-31 | |||
| 2021-12-31 | |||
| 2020-12-31 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-06-30 | ||
| 2025-03-31 | ||
| 2024-12-31 | ||
| 2024-09-30 | ||
| 2024-06-30 | ||
| 2024-03-31 | ||
| 2023-12-31 | ||
| 2023-09-30 | ||
| 2023-06-30 | ||
| 2023-03-31 | ||
| 2022-12-31 | ||
| 2022-09-30 | ||
| 2022-06-30 | ||
| 2022-03-31 | ||
| 2021-12-31 | ||
| 2020-12-31 |
Efektivitas Manajemen
- roa untuk Carisma Therapeutics, Inc. pada 2025 Jun 30 adalah -0.86.
- roe untuk Carisma Therapeutics, Inc. pada 2025 Jun 30 adalah -137.16.
| Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
| 2025-06-30 | -0.86 | -137.16 | |||
| 2025-03-31 | -0.86 | -4.66 | |||
| 2024-12-31 | -0.71 | -2.28 | |||
| 2024-09-30 | -0.68 | -1.38 | -17.60 | -8.75 | -18.36 |
| 2024-06-30 | -0.52 | -0.94 | -4.42 | -0.34 | -4.25 |
| 2024-03-31 | -1.15 | -1.69 | 1.11 | -1.68 | |
| 2023-12-31 | -0.94 | -1.69 | 1.11 | -1.68 | |
| 2023-09-30 | -0.82 | -1.11 | 0.51 | -0.97 | |
| 2023-06-30 | -0.63 | -0.75 | 0.35 | -0.66 | |
| 2023-03-31 | -0.58 | -2.86 | -0.60 | 0.23 | -0.52 |
| 2022-12-31 | -1.03 | -0.16 | 0.05 | ||
| 2022-09-30 | -1.03 | -0.16 | 0.05 | ||
| 2022-06-30 | -0.83 | -0.97 | -1.23 | -0.21 | 0.04 |
| 2022-03-31 | -0.74 | -0.86 | -0.65 | -0.24 | 0.10 |
| 2021-12-31 | -0.70 | -0.81 | -1.42 | -0.81 | -1.30 |
| 2020-12-31 | -0.53 | 0.84 | -0.50 |
Gross Margins
- marjin kotor untuk Carisma Therapeutics, Inc. pada 2025 Jun 30 adalah -1.57.
- marjin bersih untuk Carisma Therapeutics, Inc. pada 2025 Jun 30 adalah -2.54.
- marjin operasi untuk Carisma Therapeutics, Inc. pada 2025 Jun 30 adalah -2.50.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
| Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
| 2025-06-30 | -1.57 | -2.54 | -2.50 |
| 2025-03-31 | -2.13 | -3.15 | -3.29 |
| 2024-12-31 | -2.13 | -3.15 | -3.29 |
| 2024-09-30 | -2.46 | -3.50 | -3.67 |
| 2024-06-30 | -3.97 | -5.39 | -5.66 |
| 2024-03-31 | -4.04 | -5.76 | -5.45 |
| 2023-12-31 | -4.07 | -5.76 | -5.45 |
| 2023-09-30 | -4.25 | -6.07 | -5.54 |
| 2023-06-30 | -4.76 | -6.07 | -5.54 |
| 2023-03-31 | -1.28 | -6.08 | -5.63 |
| 2022-12-31 | -1.28 | -9.31 | -8.71 |
| 2022-09-30 | -1.28 | -9.31 | -8.71 |
| 2022-06-30 | -0.97 | -13.83 | -13.24 |
| 2022-03-31 | -0.97 | -52.31 | -50.91 |
| 2021-12-31 | |||
| 2020-12-31 |
Pengenal dan Deskriptor
| Kunci Indeks Pusat (CIK) | 1485003 |
Grupong Pang-industriya
| SIC 2834 - Pharmaceutical Preparations |
